nach oben

Erschienen in:

27.11.2015 | Original Article

Serum neutrophil gelatinase-associated lipocalin concentration reflects severity of coronary artery disease in patients without heart failure and chronic kidney disease

verfasst von: Mikako Katagiri, Masao Takahashi, Kent Doi, Masahiro Myojo, Arihiro Kiyosue, Jiro Ando, Yasunobu Hirata, Issei Komuro

Erschienen in: Heart and Vessels | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Serum neutrophil gelatinase-associated lipocalin (NGAL) is recognized as a useful biomarker for acute kidney injury. Recently, elevated NGAL levels were reported in patients with heart failure and cardiac events, but the association between serum NGAL and severity of coronary artery disease (CAD) has not been investigated adequately. This study aimed to evaluate the association between serum NGAL concentration and CAD severity in patients without heart failure and chronic kidney disease. Two-hundred thirteen patients [mean age: 66.2 ± 9.2 (SD)] without heart failure and chronic kidney disease (estimated glomerular filtration rate >60 mL/min/1.73 m²) who underwent coronary angiography were retrospectively analyzed using the SYNTAX score. The mean concentration of serum NGAL was 134.3 ± 111.3 ng/mL. A statistically significant correlation was observed between serum NGAL levels and the SYNTAX score (R = 0.18, P = 0.0091). Multivariable analysis also showed elevated serum NGAL as an independent risk factor for a high SYNTAX score (P < 0.01). Moreover, we evaluated the association of serum NGAL and brain natriuretic peptide (BNP) with the SYNTAX score. Patients with high levels of serum NGAL (>100 ng/mL) and high levels of BNP (>25 pg/mL) had a higher SYNTAX score (low–low vs. high–high: 13.8 ± 13.4 vs. 20.8 ± 18.9, P < 0.05). Serum NGAL levels were positively and significantly associated with CAD severity, and the evaluation of both serum NGAL and BNP was useful for predicting CAD in patients without renal dysfunction and heart failure. Serum NGAL might be a biomarker for CAD severity.

Nur mit Berechtigung zugänglich

Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW, Serruys PW (2005) The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 1(2):219–227PubMed

Serruys PW, Onuma Y, Garg S, Vranckx P, De Bruyne B, Morice MC, Colombo A, Macaya C, Richardt G, Fajadet J, Hamm C, Schuijer M, Rademaker T, Wittebols K, Stoll HP, Investigators ARTSII (2010) 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol 55(11):1093–1101CrossRefPubMed

Wykrzykowska JJ, Garg S, Girasis C, de Vries T, Morel MA, van Es GA, Buszman P, Linke A, Ischinger T, Klauss V, Corti R, Eberli F, Wijns W, Morice MC, di Mario C, van Geuns RJ, Juni P, Windecker S, Serruys PW (2010) Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial. J Am Coll Cardiol 56(4):272–277CrossRefPubMed

Sbarsi I, Falcone C, Boiocchi C, Campo I, Zorzetto M, De Silvestri A, Cuccia M (2007) Inflammation and atherosclerosis: the role of TNF and TNF receptors polymorphisms in coronary artery disease. Int J Immunopathol Pharmacol 20(1):145–154PubMed

Hemdahl AL, Gabrielsen A, Zhu C, Eriksson P, Hedin U, Kastrup J, Thorén P, Hansson GK (2006) Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 26(1):136–142CrossRefPubMed

Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P (2005) Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365(9466):1231–1238CrossRefPubMed

Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N (1993) Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 268(14):10425–10432PubMed

Alvelos M, Lourenco P, Dias C, Amorim M, Rema J, Leite AB, Guimarães JT, Almeida P, Bettencourt P (2013) Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int J Cardiol 165(1):51–55CrossRefPubMed

Maisel AS, Mueller C, Fitzgerald R, Brikhan R, Hiestand BC, Iqbal N, Clopton P, van Veldhuisen DJ (2011) Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 13(8):846–851CrossRefPubMedPubMedCentral

10.

Calabro P, Golia E, Yeh ET (2009) CRP and the risk of atherosclerotic events. Semin Immunopathol 31(1):79–94CrossRefPubMed

11.

Bogaty P, Boyer L, Simard S, Dauwe F, Dupuis R, Verret B, Huynh T, Bertrand F, Dagenais GR, Brophy JM (2008) Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study. J Am Coll Cardiol 51(24):2339–2346CrossRefPubMed

12.

Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, Nakao K, Imura H (1993) Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 87(2):464–469CrossRefPubMed

13.

Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC (1997) Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 350(9088):1349–1353CrossRefPubMed

14.

Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, Morrisey R, Garcia A, Chiu A, De Maria A (2001) Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 141(3):367–374CrossRefPubMed

15.

de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345(14):1014–1021CrossRefPubMed

16.

Palazzuoli A, Calabria P, Vecchiato L, Quatrini I, Carrera A, Bruni F, Puccetti L, Pastorelli M, Pasqui AL, Auteri A (2004) Plasma brain natriuretic peptide levels in coronary heart disease with preserved systolic function. Clin Exp Med 4(1):44–49CrossRefPubMed

17.

Goyal BM, Sharma SM, Walia M (2014) B-type natriuretic peptide levels predict extent and severity of coronary artery disease in non-ST elevation acute coronary syndrome and normal left ventricular function. Indian Heart J 66(2):183–187CrossRefPubMedPubMedCentral

18.

Zografos T, Haliassos A, Korovesis S, Giazitzoglou E, Voridis E, Katritsis D (2009) Association of neutrophil gelatinase-associated lipocalin with the severity of coronary artery disease. Am J Cardiol 104(7):917–920CrossRefPubMed

19.

Nathan DM, Balkau B, Bonora E, Borch-Johnsen K, Buse JB, Colagiuri S, Davidson MB, DeFronzo R, Genuth S, Holman RR, Ji L, Kirkman S, Knowler WC, Schatz D, Shaw J, Sobngwi E, Steffes M, Vaccaro O, Wareham N, Zinman B, Kahn R (2009) International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care 32(7):1327–1334CrossRef

20.

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Rydén L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34(28):2159–2219CrossRefPubMed

21.

Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations. Can J Cardiol 25(10):567–579CrossRefPubMedPubMedCentral

22.

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53(6):982–992CrossRefPubMed

23.

Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW, Investigators SYNTAX (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360(10):961–972CrossRefPubMed

24.

Torregrosa I, Montoliu C, Urios A, Andrés-Costa MJ, Giménez-Garzó C, Juan I, Puchades MJ, Blasco ML, Carratalá A, Sanjuán R, Miguel A (2014) Urinary KIM-1, NGAL and L-FABP for the diagnosis of AKI in patients with acute coronary syndrome or heart failure undergoing coronary angiography. Heart Vessels. doi:10.1007/s00380-014-0538-z PubMed

25.

Packard RR, Libby P (2008) Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 54(1):24–38CrossRefPubMed

26.

Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352(16):1685–1695CrossRefPubMed

27.

Saren P, Welgus HG, Kovanen PT (1996) TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol 157(9):4159–4165PubMed

28.

Galis ZS, Sukhova GK, Lark MW, Libby P (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94(6):2493–2503CrossRefPubMedPubMedCentral

29.

Galis ZS, Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90(3):251–262PubMed

30.

Tschesche H, Zolzer V, Triebel S, Bartsch S (2001) The human neutrophil lipocalin supports the allosteric activation of matrix metalloproteinases. Eur J Biochem 268(7):1918–1928CrossRefPubMed

31.

Falk E, Shah PK, Fuster V (1995) Coronary plaque disruption. Circulation 92(3):657–671CrossRefPubMed

32.

Wu JH, Hagaman J, Kim S, Reddick RL, Maeda N (2002) Aortic constriction exacerbates atherosclerosis and induces cardiac dysfunction in mice lacking apolipoprotein E. Arterioscler Thromb Vasc Biol 22(3):469–475CrossRefPubMed

33.

Nagai T, Anzai T, Mano Y, Kaneko H, Anzai A, Sugano Y, Maekawa Y, Takahashi T, Yoshikawa T, Fukuda K (2013) Eicosapentaenoic acid suppresses adverse effects of C-reactive protein overexpression on pressure overload-induced cardiac remodeling. Heart Vessels 28(3):404–411CrossRefPubMed

Titel: Serum neutrophil gelatinase-associated lipocalin concentration reflects severity of coronary artery disease in patients without heart failure and chronic kidney disease
verfasst von: Mikako Katagiri
Masao Takahashi
Kent Doi
Masahiro Myojo
Arihiro Kiyosue
Jiro Ando
Yasunobu Hirata
Issei Komuro
Publikationsdatum: 27.11.2015
Verlag: Springer Japan
Erschienen in: Heart and Vessels / Ausgabe 10/2016
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-015-0776-8

Neu im Fachgebiet Kardiologie

15.04.2024 | ACC 2024 | Kongressbericht | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Serum neutrophil gelatinase-associated lipocalin concentration reflects severity of coronary artery disease in patients without heart failure and chronic kidney disease

Abstract

Neu im Fachgebiet Kardiologie

Verbesserung der HDL-Funktion als Lipidtherapie floppt in Mega-Studie

Blutdrucksenkung per Spritze additiv zur Standardtherapie wirksam

Lässt sich die diabetische Kardiomyopathie aufhalten?

Olezarsen halbiert Triglyzeridwerte

Update Kardiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2016

Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease

Cardiovascular medicine heart failure (CVM-HF) index as prognostic model for candidates to MitraClip therapy

Repetitive restriction of muscle blood flow enhances mTOR signaling pathways in a rat model

A case of IgG4-related lymphadenopathy, pericarditis, coronary artery periarteritis and luminal stenosis

The efficacy of everolimus-eluting stent implantation in patients with ST-segment elevation myocardial infarction: outcomes of 2-year clinical follow-up

Variable severity of cardiovascular phenotypes in patients with an early-onset form of Marfan syndrome harboring FBN1 mutations in exons 24–32

Neu im Fachgebiet Kardiologie

Verbesserung der HDL-Funktion als Lipidtherapie floppt in Mega-Studie

Blutdrucksenkung per Spritze additiv zur Standardtherapie wirksam

Lässt sich die diabetische Kardiomyopathie aufhalten?

Olezarsen halbiert Triglyzeridwerte

Update Kardiologie